Is There Correlation Between Human Papillomavirus (Hpv) and Esophageal Epidermoid Carcinoma?

Abstract

Background: Currently, persistent human papillomavirus (HPV) infection has been related in some geographic regions as a risk factor for esophageal squamous cell carcinoma. It results in the immunoexpression of the p16 protein, which has been used as marker of the oncogenic lineage by this etiological agent. Aim: To correlate epidemiological aspects of esophageal squamous cell carcinoma with the prevalence of HPV infection. Methods: Fifty-eight cases were analyzed and submitted to histopathological and immunohistochemical analysis by p16. Results: Of the 58 cases evaluated, 40 were men and 18 women, with a mean age of 63.2 years. p16 immunoexpression was positive in 46.55%. Conclusion: The prevalence of HPV infection is high in esophageal squamous cell carcinoma presenting in almost half of the cases (46.55%), without gender differentiation.

Presença Do Papilomavirus Humano Tipo 16 E Expressão Gênica Da Proteína P16ink4a E Oncoproteína E7 No Carcinoma Colorretal

“…1,4,7,9,19,22 Autores mostraram a presença do HPV em tumores de outras localizações. 6,8,11,23,25,29 A expressão das oncoproteínas E6 e E7 do HPV está relacionada ao desenvolvimento dos carcinomas genitais cervicais, orais e do canal anal. 1,23,25 Os resultados apresentados em protocolo de coloração para a avaliação imuno-histoquímica da expressão das oncoproteínas E6 e E7 no câncer do colo do útero e no câncer orofaríngeo positivos para o HPV mostraram vantagens desse método em comparação com a hibridização do mRNA das proteínas E6 e E7 devido ao custo muito menor e à aplicabilidade maior na prática clínica.…”

“…In patients with anal canal tumors, a high proportion of hyperexpression of the p16 INK4a gene was identified, suggesting that HPV infection is one of the determinants for the development of anal cancer in men and women 1 , 4 , 7 , 9 , 19 , 22 . Some authors have shown the presence of HPV in tumors localized in different locations 6 , 8 , 11 , 23 , 25 , 29 .…”